SCHEMBL5491121

SCHEMBL5491121

C=CCc1c(Cl)nc(C)nc1Nc1ccc(C(F)(F)F)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.37
L3MBTL1 Q9Y468 3/20 0.36
LMNA P02545 2/20 0.36
EGFR P00533 1/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
MAPT P10636 4/20 0.36
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
RXRA P19793 4/20 0.36
NR4A2 P43354 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
GAA P10253 2/20 0.35
ALDH1A1 P00352 1/20 0.35
CTSC P53634 1/20 0.35
KDM4E B2RXH2 2/20 0.34
GLA P06280 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3288568 0.85 THRB (0.41) L3MBTL1LMNAMAPTMEN1KMT2A
SCHEMBL5496988 0.78 SMO (0.36) LRRK2LMNAEGFRPDGFRBKDR
SCHEMBL2191701 0.74 TRPV1 (0.36) LRRK2L3MBTL1EGFRPDGFRBKDR
SCHEMBL4503972 0.73 LRRK2 (0.38) LRRK2L3MBTL1MAPTMEN1KMT2A
SCHEMBL5496929 0.72 CRHR1 (0.40) MAPTMEN1KMT2APOLBMAPK1
SCHEMBL4765655 0.69 MEN1 (0.34) LRRK2LMNAMAPTMEN1KMT2A
SCHEMBL2190430 0.69 EGFR (0.33) LRRK2LMNAEGFRPDGFRBKDR
SCHEMBL2189399 0.68 THRB (0.43) LMNAEGFRKDRMAPTMEN1
SCHEMBL3277032 0.67 GAA (0.39) L3MBTL1LMNAMAPTMEN1KMT2A
SCHEMBL20751779 0.65 PDE2A (0.38) POLBGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279474-B2 Substituted pyrrolo[2,3-d]pyrimidines as antagonists of the corticotropin releasing factor (CRF) GLAXO GROUP LIMITED (GB) 2007-10-09 US disclosed
US-20040176400-A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) GLAXO GROUP LIMITED (GB) 2004-09-09 US disclosed
EP-1383747-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2004-01-28 EP disclosed
WO-2002088095-A1 FUSED PYRIMIDINES AS ANTAGONISTS OF THE CORTICOTROPIN RELEASING FACTOR (CRF) GLAXO GROUP LIMITED (GB) 2002-11-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176400-A1 Fused pyrimidines as antagonists of the corticotropin releasing factor (crf) CRH, CRHR1, CRHR2 LRRK2 2873/4885L3MBTL1 4675/4885LMNA 4763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.